Renaissance Technologies LLC Grows Stock Position in Emergent Biosolutions Inc. $EBS

Renaissance Technologies LLC raised its position in Emergent Biosolutions Inc. (NYSE:EBS) by 13.7% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 656,047 shares of the biopharmaceutical company’s stock after buying an additional 78,900 shares during the quarter. Renaissance Technologies LLC owned about 1.27% of Emergent Biosolutions worth $5,445,000 at the end of the most recent reporting period.

Other institutional investors have also recently made changes to their positions in the company. Dimensional Fund Advisors LP increased its holdings in Emergent Biosolutions by 22.4% in the 1st quarter. Dimensional Fund Advisors LP now owns 2,757,158 shares of the biopharmaceutical company’s stock worth $22,884,000 after acquiring an additional 504,553 shares during the last quarter. State Street Corp raised its stake in Emergent Biosolutions by 10.2% in the 4th quarter. State Street Corp now owns 2,696,375 shares of the biopharmaceutical company’s stock valued at $33,327,000 after acquiring an additional 250,616 shares during the period. Millennium Management LLC lifted its holdings in Emergent Biosolutions by 68.9% during the first quarter. Millennium Management LLC now owns 2,502,488 shares of the biopharmaceutical company’s stock valued at $12,162,000 after purchasing an additional 1,020,582 shares during the last quarter. Charles Schwab Investment Management Inc. lifted its holdings in Emergent Biosolutions by 17.2% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 1,618,903 shares of the biopharmaceutical company’s stock valued at $20,010,000 after purchasing an additional 237,153 shares during the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd. boosted its position in Emergent Biosolutions by 14.8% during the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 1,132,305 shares of the biopharmaceutical company’s stock worth $9,987,000 after purchasing an additional 145,632 shares during the period. Hedge funds and other institutional investors own 78.40% of the company’s stock.

Analyst Ratings Changes

Several equities analysts have recently weighed in on EBS shares. Weiss Ratings downgraded shares of Emergent Biosolutions from a “sell (d)” rating to a “sell (d-)” rating in a research note on Monday, May 11th. Benchmark reaffirmed a “buy” rating on shares of Emergent Biosolutions in a report on Tuesday, June 2nd. Finally, UBS Group reiterated a “buy” rating on shares of Emergent Biosolutions in a research note on Tuesday, June 2nd. Three equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company currently has an average rating of “Hold” and an average target price of $12.00.

Emergent Biosolutions Stock Performance

Shares of EBS opened at $7.55 on Thursday. Emergent Biosolutions Inc. has a 52-week low of $6.03 and a 52-week high of $14.06. The stock’s 50-day simple moving average is $7.98 and its 200 day simple moving average is $8.83. The company has a debt-to-equity ratio of 1.10, a quick ratio of 2.08 and a current ratio of 4.29. The stock has a market capitalization of $389.84 million, a price-to-earnings ratio of -26.98 and a beta of 2.35.

Emergent Biosolutions (NYSE:EBS) last posted its earnings results on Wednesday, August 5th. The biopharmaceutical company reported $0.60 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.08) by $0.68. Emergent Biosolutions had a positive return on equity of 10.76% and a negative net margin of 1.27%.The business had revenue of $234.30 million during the quarter, compared to analyst estimates of $177.50 million.

Insider Activity at Emergent Biosolutions

In related news, SVP Paul Anthony Williams sold 3,000 shares of the business’s stock in a transaction that occurred on Wednesday, July 1st. The shares were sold at an average price of $8.40, for a total transaction of $25,200.00. Following the completion of the transaction, the senior vice president owned 159,098 shares of the company’s stock, valued at approximately $1,336,423.20. The trade was a 1.85% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 6.00% of the company’s stock.

About Emergent Biosolutions

Emergent BioSolutions is a global specialty biopharmaceutical company focused on developing, manufacturing and commercializing medical countermeasures and specialty products that address public health threats. The company’s portfolio includes vaccines, antibody therapies and critical care products designed to protect against biological, chemical and emerging infectious disease threats. Emergent has longstanding partnerships with government agencies, including the U.S. Department of Defense and the Biomedical Advanced Research and Development Authority (BARDA), to support national preparedness programs.

Key commercial products in Emergent’s lineup include BioThrax (anthrax vaccine adsorbed), ACAM2000 (smallpox vaccine) and Vaxchora (cholera vaccine), alongside therapeutic treatments such as Anthrasil (anthrax immune globulin) and the naloxone-based nasal spray Narcan for opioid overdose reversal.